Cantor Fitzgerald Estimates VERV FY2025 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Verve Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will post earnings per share of ($2.67) for the year. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share.

Several other research analysts have also recently issued reports on VERV. HC Wainwright lowered their price objective on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada cut their price target on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group lifted their target price on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 6th.

Verve Therapeutics Trading Up 18.7 %

Shares of NASDAQ:VERV opened at $7.80 on Wednesday. Verve Therapeutics has a 52 week low of $4.30 and a 52 week high of $19.34. The company’s 50 day moving average is $5.84 and its two-hundred day moving average is $5.79. The company has a market cap of $660.35 million, a PE ratio of -3.17 and a beta of 1.68.

Verve Therapeutics (NASDAQ:VERV) last issued its earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.11. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The firm had revenue of $6.87 million for the quarter, compared to analysts’ expectations of $2.75 million. During the same quarter last year, the company earned ($0.72) earnings per share. The firm’s revenue was up 120.2% compared to the same quarter last year.

Institutional Investors Weigh In On Verve Therapeutics

Large investors have recently modified their holdings of the stock. Accredited Investors Inc. raised its stake in shares of Verve Therapeutics by 14.3% during the 3rd quarter. Accredited Investors Inc. now owns 20,000 shares of the company’s stock worth $97,000 after buying an additional 2,500 shares in the last quarter. Green Alpha Advisors LLC lifted its holdings in Verve Therapeutics by 15.0% in the fourth quarter. Green Alpha Advisors LLC now owns 29,438 shares of the company’s stock valued at $166,000 after acquiring an additional 3,840 shares during the period. FMR LLC grew its stake in shares of Verve Therapeutics by 0.3% during the 3rd quarter. FMR LLC now owns 1,418,993 shares of the company’s stock worth $6,868,000 after purchasing an additional 3,873 shares during the period. GAMMA Investing LLC increased its holdings in shares of Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock valued at $34,000 after purchasing an additional 3,964 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Verve Therapeutics by 20.4% in the second quarter. The Manufacturers Life Insurance Company now owns 28,105 shares of the company’s stock valued at $137,000 after purchasing an additional 4,759 shares during the period. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.